Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 22, 2010. The filing serves as a Regulation FD disclosure to announce an upcoming investor conference call scheduled for March 23, 2010. The call will cover financial results for the year ended December 31, 2009, and provide an update on the suspension of work under a modified contract with BARDA for the development of SparVax.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as topics for the upcoming conference call but are not disclosed within this document.
Material Changes
The primary material event disclosed is the suspension of work under a modification to the Company's existing contract with BARDA regarding the research and development of SparVax. This update was previously announced on February 23, 2010, and further details are expected during the March 23 conference call.
Guidance, Outlook, and Risks
- Management Commentary: Management plans to discuss the 2009 financial results and the status of the BARDA contract suspension during the scheduled conference call.
- Outlook: No specific forward-looking guidance or financial projections are included in this filing.
- Risks/Contingencies: The suspension of work on the SparVax contract represents a significant operational contingency affecting the Company's development pipeline.
Key Facts for Investor Verification
- Verify the specific financial results for the fiscal year ended December 31, 2009, once the conference call transcript or subsequent filings are released.
- Confirm the reasons for the suspension of work on the BARDA SparVax contract and the potential impact on future funding or revenue.
- Note that the registrant name in the filing is PharmAthene, Inc., which may differ from the company name provided in the request metadata.
- Check for any subsequent filings regarding the resolution of the contract suspension or changes in the Company's strategic direction.